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Abstract
Human genetic association studies have shown gene variants in the α5 subunit of the neuronal nicotinic receptor
(nAChR) influence both ethanol and nicotine dependence. The α5 subunit is an accessory subunit that facilitates α4*
nAChRs assembly in vitro. However, it is unknown whether this occurs in the brain, as there are few research tools to
adequately address this question. As the α4*-containing nAChRs are highly expressed in the ventral tegmental area
(VTA) we assessed the molecular, functional and pharmacological roles of α5 in α4*-containing nAChRs in the VTA.
We utilized transgenic mice α5+/+(α4YFP) and α5-/-(α4YFP) that allow the direct visualization and measurement of
α4-YFP expression and the effect of the presence (α5+/+) and absence of α5 (-/-) subunit, as the antibodies for
detecting the α4* subunits of the nAChR are not specific. We performed voltage clamp electrophysiological
experiments to study baseline nicotinic currents in VTA dopaminergic neurons. We show that in the presence of the
α5 subunit, the overall expression of α4 subunit is increased significantly by 60% in the VTA. Furthermore, the α5
subunit strengthens baseline nAChR currents, suggesting the increased expression of α4* nAChRs to be likely on
the cell surface. While the presence of the α5 subunit blunts the desensitization of nAChRs following nicotine
exposure, it does not alter the amount of ethanol potentiation of VTA dopaminergic neurons. Our data demonstrates
a major regulatory role for the α5 subunit in both the maintenance of α4*-containing nAChRs expression and in
modulating nicotinic currents in VTA dopaminergic neurons. Additionally, the α5α4* nAChR in VTA dopaminergic
neurons regulates the effect of nicotine but not ethanol on currents. Together, the data suggest that the α5 subunit is
critical for controlling the expression and functional role of a population of α4*-containing nAChRs in the VTA.
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Introduction
Neuronal nicotinic acetylcholine receptors (nAChRs) are
pentameric ligand-gated ion channels with a vast diversity of
subtypes [1]. The different nAChR subtypes are made up of α2-6
and β2-4 subunits in the heteromeric form or α7-10 subunits in the
homomeric form, where each subunit is encoded by a distinct
gene [2,3]. The nAChRs are abundant in several brain areas
including the ventral tegmental area (VTA) [4,5], which is part
of the midbrain dopaminergic reward system [6,7]. The subunit
composition of nAChR is dependent on the brain region and
neuronal type [8–11]. The α4β2* (*denotes the possibility that
other nAChR subunits are present in the pentameric nAChR),
and α7 are the most highly expressed subtype in the brain
[12,13].
A wide range of pharmacological compounds have been
found to activate nAChRs [14]. The neurotransmitter
acetylcholine (ACh) is an endogenous agonist that can bind
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and activate nAChRs [15]. ACh or an exogenous agonist such
as nicotine has a distinct binding site that is different from
allosteric modulators such as ethanol [14]. The
pharmacological, Ca2+ permeability and desensitization
properties of these ion channels to different agonists such as
ACh, nicotine or ethanol are influenced by the subunit
composition of the nAChR. For example the α4β2* compared
to α7 nAChRs have a slower nicotinic current kinetics with
reduced Ca2+ ion permeability and a stronger desensitization to
nicotine [16–19].
Recent human genetic association studies identified variants
in the CHRNA5 gene encoding the α5 nAChR subunit have the
risk of developing ethanol or nicotine dependence [20–23].
Hence, the α5* nAChRs may be a promising target for alcohol
and nicotine cessation therapy. The VTA plays a key role in the
acquisition of behaviors reinforced by addictive drugs such as
ethanol and nicotine [6,7], and both nicotine and ethanol can
activate VTA neurons via nAChRs [24–26]. The VTA has a
high concentration of the α4β2* nAChR subtype, predominantly
found in dopaminergic and GABAergic neurons, and the α7
nAChRs on presynaptic glutamatergic terminals [24,27,28].
α5 is an accessory subunit that does not contribute to the
formation of agonist binding site and is only co-expressed with
other α and β nAChR subunits. It is present in high
concentrations in the VTA, and is thought to be an important
component of the putative functional (α4β2) 2α5 nAChR
subtype expressed in this region [4,29]. Cell-based
heterologous expression systems have been widely used along
with recent animal behavioral studies to understand α5 nAChR
pharmacology. The presence of α5 subunits in α4* nAChRs
produces larger nicotinic currents and modifies ACh sensitivity
of α4*-containing nAChRs in cultured neurons and prefrontal
cortex [30–33]. Behaviorally, the α5 nAChR subunit has been
strongly associated with nicotine’s effects in rodents, since
α5-/- mice display altered anxiety-related behavior [34], low
sensitivity to high doses of acute nicotine [35] and increased
nicotine intake at very high aversive doses [36]. Recently, it
was shown that α5 nAChR subunit is important for the sedative
effects of ethanol but not consumption in mice (Santos et al.,
2012). However, nothing is known so far about the expression
and functional contribution of α5 for nicotine and ethanol in the
ventral tegmental area of the brain.
Specific nAChR subunits have been impossible to visualize
and quantify expression of in vivo because of the lack of
subtype specific tools. Here, we have developed a novel
mouse line by crossing α5 nAChR deficient mice with α4-YFP
nAChR knock-in (KI) mice, allowing us to directly determine the
role of α5 in regulating protein expression of α4*-containing
nAChRs in the brain. We found α5 to play a key role in
controlling the expression of α4*-containing nAChRs in the VTA
that likely affects the strength of nicotinic receptor currents of
VTA dopamine neurons studied here. Additionally, the
presence of α5 appears to play no additional functional role in
ethanol’s effect on nAChRs in ventral tegmental area.
Methods and Materials
Animals and Housing
All mice were housed in climate controlled rooms with food
and water available ad libitum. Mice were housed 2-5 per cage
on a 12 hour light/dark cycle (lights on 7am).
Ethical Considerations
The experiments contained herein comply with the laws of
USA. All procedures were pre-approved by the Gallo Center
ethics committee and were in accordance with NIH guidelines
for the Humane Care and Use of Laboratory Animals.
α5 nAChR deficient mice
The α5-/- mice were generously provided by Dr. Jerry Stitzel
(Institute for Behavioral Genetics, University of Colorado), and
had been backcrossed at least 10 generations on a C57BL/6J
background. The α5+/+ mice and α5-/- littermate mice used
here were generated from heterozygous breeding pairs. The
α5-deficient mice have a healthy appearance and no
abnormalities in a standard battery of behavioral tests [35].
α4YFP, α5+/+(α4YFP) and α5-/-(α4YFP) mice
The α4YFP knock-in mice (α4 nAChR subunit tagged with
yellow fluorescent protein (YFP)) generated by the Lester Lab
(Caltech) had been backcrossed on a C57BL/6J background
for at least 10 generations [37]. The α4YFP mice retained the
receptor function when fluorescent proteins were inserted into
the intracellular M3-M4 intracellular loop of the α4 subunit. In
addition, the tagged α4 nAChRs displayed similar localization
patterns in the brain and are under the control of the same
promoters, enhancers and trafficking mechanisms as the WT
α4 [38]. Two further generations of backcrossing were
performed after arrival. The mice used in this study were
generated from homozygous breeding pairs. The α4-YFP mice
have a healthy appearance and receptor function and have
been shown to be similar to wild-type mice [38].
To be able to directly visualize and measure the contribution
of α5 to α4 subunit regulation, α5+/+ and α5-/- mice were
cross-bred with the α4YFP mice to create α5+/+(α4YFP) and
α5-/-(α4YFP) mice. Homozygous α5-/- mice were bred with
homozygous α4YFP mice to produce heterozygous α5+/-
heterozygous α4YFP mice. The male and female heterozygous
α5+/- and heterozygous α4YFP littermates were then mated.
From these offspring heterozygous α5+/- and homozygous
α4YFP littermates were mated such that all offspring produced
from these pairs possessed both α4YFP genes with only the
number of α5 subunit genes varying between the offspring. The
α5+/+(α4YFP) mice have a healthy appearance and did not
appear to be different from α5-/-(α4YFP) mice. Genotyping for
α5 nAChR-deficient, α4YFP, α5+/+(α4YFP) and α5-/-(α4YFP)
mice was performed using polymerase chain reaction as
previously described for the α5 gene [35] and the α4YFP gene
[37].
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Immunohistochemistry and Imaging
Male α5+/+(α4YFP) and α5-/-(α4YFP) mice (p35-p56 age)
were deeply anesthetized with 200 mg/kg Euthasol® (Virbac,
TX) and intracardially perfused with 0.9% NaCl, followed by 4%
paraformaldehyde (Sigma-Aldrich, MO). Extracted brains were
further fixed in 4% paraformaldehyde for 4 hours and 30%
sucrose for 2 days. 50 µm frozen sections were prepared using
a Microm cryostat (Thermo, Fisher Scientific, MA). Free-
floating horizontal sections containing the VTA were stained
with FITC-conjugated goat anti-GFP polyclonal antibody, also
recognizing YFP (1:1000, ab6662, Abcam, MA) [39,40], mouse
anti-Tyrosine Hydroxylase monoclonal antibody (1:2000, TH,
Sigma-Aldrich, MO) followed by Alexa Fluor 594-labeled
donkey anti-mouse secondary antibody (1:300, Invitrogen, CA)
before mounting on slides. In addition to YFP and TH markers,
we also performed triple-labeling experiments by adding a
rabbit polyclonal antibody recognizing GAD65/67 (1: 500;
Millipore) followed by Alexa Fluor 594-conjugated donkey anti-
rabbit secondary antibody, and the TH was visualized with
Alexa Fluor 647-conjugated donkey anti-mouse secondary
antibody. Images were acquired using a Zeiss LSM 510 META
laser confocal microscope (Zeiss MicroImaging, Thornwood,
NY, US) or Nikon Eclipse Ti-E Motorized Inverted Microscope
(Nikon Instruments Inc, Melville, NY). VTA images were taken
in areas similar to those used for electrophysiology immediately
medial to the medial terminal nucleus of the accessory optic
tract (MT) in primarily the more ventral sections containing the
VTA (43). Images were processed using the Imaris
Neuroscience software pack (v.7.1.1, Andor Technology,
Belfast, Northern Ireland); the colocalization study for the YFP
protein and the TH or GABA protein was performed using
ImageJ plugins (v 1.43m) (NIH).
Western Blots
Preparation of homogenates.  Brains were harvested from
male α5+/+(α4YFP) and α5-/-(α4YFP) at p35-p70 age and 1
mm coronal sections were made using an ice cold brain matrix
(Australian National University). Section(s) containing the VTA
were placed on an ice cold platform and dissected under a
microscope (Leica S6D, IL) and stored at -80°C. On the day of
the analysis, VTA were thawed and then homogenized in lysis
buffer (phosphate buffered saline containing 0.1% Triton-X and
complete mini-protease inhibitor) with 0.5 mm glass beads
using the Bullet Blender (Next Advance, NY) at 4°C. Protein
concentration was determined using Bradford protein reagent
(BioRad, CA) and the SpectroMax spectrophotometer
(Molecular Devices, CA). Samples were diluted to the
appropriate concentration (20 µg/lane) in reducing sample
buffer (Pierce Protein Research Products, IL) and incubated at
37°C for 30 min.
Protein separation and Analysis.  Proteins were separated
using SDS-PAGE with 4-20% tris-glycine gels and transferred
under ice cold conditions to a nitrocellulose membrane.
Membranes were blocked in phosphate-buffered saline
containing 5% milk and 0.05% Tween 20 then probed with
primary antibodies at 4°C overnight. Rabbit polyclonal antibody
against GFP (1:2500, ab290, Abcam, MA) and mouse
monoclonal anti-GAPDH antibody (1:10000, MA1-22670,
Affinity Bioreagents Inc, CO) were used. Appropriate Dylight
800-conjugated secondary antibodies (1:10000, Rockland
Immunochemicals, PA) were used for band detection with the
Odyssey Infrared Imaging System (LI-COR Biosciences, NE).
Band densities were measured using Odyssey Application
Software version 2.0.40 (LI-COR Biosciences, NE). An
exclusion criterion was applied and α4-YFP expression levels
of less than 1% of GAPDH were removed from both genotypes.
Electrophysiology
Male mice (P21-31) were deeply anesthetized and perfused
transcardially with ~ 20 ml of ice-cold modified artificial
cerebrospinal fluid (aCSF): 75 sucrose; 87 NaCl, 2.5 KCl, 1.25
NaH2PO4, 7 MgCl2, 0.5 CaCl2, 25 NaHCO3, saturated with 95%
O2-5% CO2. Horizontal VTA brain slices (200 µm) were
prepared in the same solution and recovered for at least 1hr at
31°C in aCSF, osmolarity 304-306, containing (in mM): 126
NaCl, 2.5 KCl, 1.1 NaH2PO4, 1.4 MgCl2, 2.4 CaCl2, 11 D-
glucose and 26 NaHCO3 with ascorbic acid (1 mM) added just
before the first slice.
Whole-cell voltage-clamp recordings made with Multiclamp
700B amplifier using Clampex 9.0 acquisition software
(Molecular Devices, Sunnyvale) with acquisition rate of 10KHz
and low-pass filtering at 2KHz. Experiments were performed on
VTA dopaminergic neurons located immediately medial to the
medial terminal nucleus (MT) of the accessory optic tract and
identified by the detection of a large Ih current [41,42].
Recently, studies have shown that the presence of an Ih current
does not unequivocally identify DA neurons [43]. We were
consistent in our patching area where majority of Ih positive
neurons are dopaminergic neurons (TH positive) [41,42].
Hence, it’s likely that the number of Ih positive TH negative
neurons that contributed to this study is very small. Neurons
were held at -70 mV and recordings made with 3-5 MΩ
resistance patch-pipettes using a cesium-based internal
solution containing: 117 mM cesium methanesulphonate, 20
mM HEPES, 0.4 mM EGTA, 2.8mM NaCl, 5 mM TEA-Cl,
2.5mg/ml Mg-ATP and 0.25 mg/ml Mg-GTP, at pH=7.2-7.4 and
osmolarity 280-285. The input resistance (Ri) and series
resistance (Rs) were continuously monitored throughout the
recording and cells with any large deviations of these
properties were not included in the analysis. All
pharmacological experiments included atropine (1 µM) in aCSF
to block muscarinic acetylcholine receptors.
Nicotinic currents were activated by pressure application of
acetylcholine (ACh, 1 mM) via picospritzer pipettes (10 psi,
Parker Hannifin Instrument, Cleveland, OH) (adapted from
[18]). Neurons with stable holding current for 5 min were puffed
with ACh estimated to be ~20 µM from the neuron for 300 ms
every 2 min for 6 min. The average of the three peak inward
currents (evoked every 2 min across 6 min) was taken to be
the baseline was calculated relative to the holding current 500
ms immediately before the ACh puff using Clampfit 9.0
acquisition software (Molecular Devices, Sunnyvale, CA). A
drug was then bath applied for 10 min during which time ACh
was puffed every 2 min followed by 10 min wash-out period.
The amplitude of the ACh-induced current at each time point
was measured as percent change of baseline current induced
α5 nAChR Regulates α4 nAChR Expression in the VTA
PLOS ONE | www.plosone.org 3 July 2013 | Volume 8 | Issue 7 | e68300
by the drug: [(amplitude of ACh-induced current at x min)) /
amplitude of ACh-induced baseline current] X 100. The drugs
used here were nicotine (0.3 µM and 1 µM), ethanol (60 mM
and 80 mM), dihydro-β-erythroidine (DHβE, 2 µM),
methyllycaconitine (MLA, 5 nM) or tetrodotoxin (2 µM). Only
one drug concentration was applied per neuron. We observed
a low incidence of fast nAChR currents which could be
because of not using a computer-controlled motorized puffer
that could be retracted after puffing. Hence, any agonist
leakage could potentially cause a loss or underestimate the
fast component elicited by mainly the α7 nAChR [18].
Drugs
The 95% (v/v) ethanol (Gold Shield Chemical Co, CA),
nicotine hydrogen tartrate, atropine, DHβE, MLA, tetrodotoxin,
acetylcholine chloride (Sigma-Aldrich, MO) solutions were
prepared fresh daily for all experiments.
Statistics
We used Graph Pad Prism (Graph Pad, CA) or Sigma Stat
(Systat Software, CA), using two-way, one-way ANOVA or un-
paired t-test wherever applicable with Newman–Keuls post hoc
analysis when a significant effect was found (p < 0.05).
Results
α5 subunits help maintain the expression of α4*-
containing nAChR in the VTA
The α4*-containing nAChRs are highly expressed in the VTA
[44]. The α5 functions as an accessory subunit and assembles
predominantly with the α4*-containing nAChRs in the VTA
[1,29]. We wanted to first examine whether the presence of α5
is critical for maintaining VTA α4 protein levels. Since
visualization and quantification of nAChRs has been difficult
due to lack of specific antibodies; we utilized transgenic mice in
which the α4 subunit of nAChRs is fused with yellow
fluorescent protein (YFP) to which available specific antibodies
can be effectively used in western blot analysis to quantify α4
protein levels. To assess the role of the α5 nAChR subunit in
regulating α4 protein levels, we crossed α4YFP knock-in mice
with the α5 knockout mice to generate α5+/+(α4YFP) and α5-/-
(α4YFP) mice (see Materials and Methods). These mice were
normal in their weight, appearance and showed no obvious
signs of physical or neurobiological deficits. They had good
fertility and produced expected proportions of transgenic mice
from mating and were viable.
Using anti-GFP(YFP) antibodies in western blot analysis, we
found that the α4YFP expression measured in VTA tissue
sections (see Materials and Methods) was significantly reduced
in the α5-/-(α4YFP) (7.84 ± 2.7, n=6 animals) when compared
to α5+/+(α4YFP) mice (19.67 ± 4.2, n=8 animals) (two-tailed
unpaired t test, *p<0.05, Figure 1A& B). Hence, the absence of
α5 causes a substantial reduction in the α4 subunit expression
in the total tissue homogenates of the VTA.
The α4* nAChRs are found in both dopaminergic and
GABAergic neurons of the VTA [44,45]. Semi-quantitative
colocalization analysis of the VTA that correspond to areas
where we performed electrophysiology in α5+/+(α4YFP) and
α5-/-(α4YFP) mice showed that α4YFP is co-expressed in the
majority of TH-positive dopaminergic neurons in both
genotypes (Figure 2A& B) (α5+/+(α4YFP): n=2 animals; α5-/-
(α4YFP): n=3 animals). Triple-staining with antibodies against
GFP (YFP), GAD65/67 (GABAergic marker) and TH shows that
GAD65/67-positive perikarya express much less YFP than
adjacent TH-positive dopaminergic cells which extend the data
previously described by (Nashmi et al., 2007) (38) (Figure 2C).
α5 subunits enhance the strength of α4* nicotinic
currents in VTA dopaminergic neurons
To assess the functional effect of reduced α4 protein levels,
we examined here the nAChR activation of dopaminergic
neurons in VTA brain slices from α5+/+ and α5-/- mice. Patch
experiments were performed in neurons near the medial
terminal nucleus of the accessory optic tract (MT), where the Ih
current typically indentifies dopaminergic neurons in mice
[41,46]; putative dopaminergic neurons were thus identified by
the presence of an Ih current [18,19,42] Figure 3A). We
performed whole-cell voltage clamp recordings at -70 mV, and
nAChR currents were elicited by puff application of ACh (1 mM,
300 ms, applied every 2 min) (Figure 3B) in the presence of
atropine (1 µM) to block muscarinic acetylcholine receptors.
We found that the peak amplitude of the nicotinic current
elicited by ACh was significantly smaller in α5-/- neurons (65.1
± 3.7 pA, n=61 cells across 50 animals) compared to α5+/+
neurons (83.2 ±5.8 pA, n=57 cells across 45 animals) neurons
(two-tailed unpaired t test, **p<0.01, Figure 3C). We found no
difference between the capacitance value of these cells
between α5+/+ and α5-/-mice (α5+/+: 77.85 ± 5.4; α5-/-: 72.64
±3.8). However the net charge (pA/pF) calculated for these
neuronal cells also determined a significant difference (α5+/+:
1.196 ± 0.1938; α5-/-: 0.7455 ± 0.05617; two-tailed unpaired t
test, *p<0.05, Figure 3D).
Figure 1.  The α5 subunit plays an importantrole in
maintaining α4* nAChR levels.  (A and B) The α5-/-(α4 YFP)
mice have significantly reduced α4YFP expression levels in the
VTA compared with α5+/+(α4 YFP) quantified using western
blot analysis. The values are expressed as mean α4 YFP
expression (% of GAPDH) ± SEM (two-tailed unpaired t-test, *
p=0.05). n=6-8 number of animals (two-tailed unpaired t-test,
*p<0.05).
doi: 10.1371/journal.pone.0068300.g001
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Importantly, almost all evoked nAChR currents were
sensitive to the α4* nAChR antagonist dihydro-β-erythroidine
(DHβE) (2 µM, 10 min, n=4-6 per genotype, Figure 3 E& F); the
percent of baseline current following DHβE application was
25.6 ± 2.5% (n=7 cells across 6 animals) for α5+/+ and 28.4 ±
3.4% (n=7 cells across 6 animals) for α5-/- mice (Figure 3G)
(two-tailed unpaired t test, n.s). This confirmed that the ACh-
evoked current predominantly reflected α4*-containing
receptors, and that α4* currents were reduced in the absence
of α5 subunits. Currents with a fast component [18] were rarely
observed, and were inhibited by the α7 nAChR antagonist MLA
(5 nM, 10 min) in both genotypes (data not shown). In addition,
ACh-evoked currents were not reduced by the sodium channel
blocker tetrodotoxin (2 µM, 10 min, n=3-5 per genotype, Figure
3K), suggesting that ACh-evoked currents did not reflect
changes in presynaptic release and instead represented
postsynaptically-evoked nAChR-mediated currents. Finally,
repeated ACh puffing led to currents that were stable in
amplitude for >20 min in neurons exposed only to aCSF in both
α5+/+ (Figure 3H) and α5-/- (Figure 3I), suggesting that this
method could reliably be used in subsequent experiments
examining changes in nAChR currents with exposure to
ethanol and nicotine. The percent of baseline current following
20 min puffing ACh in the presence of aCSF was 106.6 ± 4.3%
(n=6 cells across 5 animals) for α5+/+ and 102 ± 7.4% (n=6
cells across 6 animals) for α5-/- mice (Figure 3J) (two-tailed
unpaired t test, n.s).
Figure 2.  The α4 nAChR is colocalized with TH-positive
dopaminergic neurons of the VTA.  Representative
immunofluorescence images from α5+/+(α4 YFP) (A) and α5-/-
(α4 YFP) (B and C); VTA showing α4 nAChR-YFP expression
(green), tyrosine hydroxylase (TH) (red) expression, the
merged images (green + red) and the colocalization (yellow);
VTA showing α4 nAChR-YFP expression (green), GAD65/67
(red), tyrosine hydroxylase (TH) (blue) expression, and the
merged images (green + red + blue). Scale bar is 30µm.
doi: 10.1371/journal.pone.0068300.g002
Figure 3.  The α5 subunit controls the strength of nicotinic
currents mediated by the α4*-containing nAChRs in VTA
dopaminergic neurons.  (A) A typical Ih current. (B) Sample
voltage clamp traces of peak inward current of DA neurons to a
300 ms ACh (1mM) puff in α5+/+ (black) and α5-/- mice (gray).
(C) The average ACh-induced peak current amplitude was
reduced in dopaminergic neurons from α5-/- mice in
comparison to α5+/+ mice. (D) The average net charge was
reduced in dopaminergic neurons from α5-/- mice in
comparison to α5+/+ mice. (E and F) Both α5+/+ (black) (E)
and α5-/- (gray) (F) mice showed a nearly complete reduction
in the nicotinic currents after 10 min of α4 nAChR antagonist
DHβE (2µM) treatment indicating that the responses are
mediated by the α4* nAChRs. (G) The percent reduction from
baseline following DHβE treatment were similar for α5+/+ and
α5-/- mice. (G and H) Currents were stable to 300ms ACh
puffing every 2 min for 20 min in neurons exposed to aCSF in
both α5+/+ (black) (H) and α5-/- (gray) (I). (J) There was no
significant percent reduction from baseline in both genotypes.
(K) TTX (2 µM) had no effect on the current in both α5+/+ and
α5-/- mice. In C & D, n = 57-61 cells across 45-50 animals, F, n
=7 cells across 6 animals and in I, n=6 cells across 5-6
animals. The values in C are mean peak amplitude ±SEM (two-
tailed unpaired t-test, **p<0.01). The values in F&I are reported
as mean percent of baseline ±SEM (two-tailed unpaired t-test).
The calibrations for the current trace are 100pA, 15 sec (A) and
25pA, 0.5sec (B, E and H).
doi: 10.1371/journal.pone.0068300.g003
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α5α4* nAChR subunits reduce receptor desensitization
during nicotine exposure
It is well known that nAChRs undergo desensitization, a
reversible reduction in current response with prolonged
application of an agonist such as nicotine [19,32], including in
VTA dopaminergic neurons [19]. Here, we examined the effect
of bath application of nicotine (0.3 µM and 1 µM, 10 min) on
ACh-induced currents in VTA dopaminergic neurons in slices
taken from α5+/+ and α5-/- mice. The average of three ACh-
induced current responses (evoked every 2 min across 6 min)
was considered as baseline, and responses in the presence of
nicotine represented as percent of baseline (see Materials and
Methods). Continued exposure to nicotine reduced the
amplitude of ACh-induced currents (Figure 4A) in both the
α5+/+ and α5-/- neurons, and nAChR desensitization was
significantly greater in the absence of the α5 subunit (Figure
4B). Two-way ANOVA analysis of percent reduction from
baseline for 0.3 µM nicotine revealed a significant effect of
genotype (F(1,128) = 14.05, p<0.001), exposure time (F(7,128)
= 32.66, p<0.001) and genotype-time interaction (F(7,128) =
2.15, p<0.05), with post-hoc analysis indicating a greater
reduction in α5-/- versus α5+/+ at 10-16 min (Figure 4B). The
percent baseline current following 10 min application of 0.3 µM
nicotine was 69.2 ± 5% (n=9 cells across 9 animals) for α5+/+
and 47.7 ± 3.4 (n=8 cells across 8 animals) for α5-/- mice
(Figure 4C). For the 1 µM dose of nicotine, two-way ANOVA
analysis revealed a significant effect of time (F(7,159) = 71.07,
p<0.001) and genotype (F(1,159) = 4.13, p<0.05) but no effect
on genotype-time interaction (F(7,159) = 1.41, n.s) (α5+/+:
49.9±3.7%, n=10 cells across 9 animals; α5-/-: 36.7±3.8%, n=9
cells across 8 animals).
α5α4* nAChR does not affect ethanol-mediated
potentiation of ACh-induced nicotinic current
Ethanol has been shown to potentiate ACh-induced nicotinic
currents in cultured neurons [15]. To the best of our knowledge,
we demonstrate for the first time that ethanol (60 mM and 80
mM, Figure 5A) can significantly increase the amplitude of
ACh-induced currents in VTA dopaminergic neurons of α5+/+
and α5-/- mice. We found no difference in the level of ethanol-
induced potentiation of ACh-induced currents in the absence or
presence of α5 subunit. A two-way ANOVA revealed a
significant effect of 80 mM ethanol exposure time (F(7,128) =
24.96, p<0.001) but no effect of genotype (F(1,128) = 0.77, n.s)
or genotype-time interaction (F(7,128) =0.319, n.s). Post hoc
analysis revealed no significant effect (Figure 5B). Similarly, a
two-way ANOVA analysis revealed a significant effect of 60
mM ethanol exposure time (F(7,64) = 11.97, p < 0.001) but no
effect of genotype (F(1,64) = 1.707, n.s) or genotype-time
interaction (F(7,64) = 0.55, n.s) (Figure 5C). The percent of
baseline current following 10 min application of 80 mM ethanol
was 161.2 ± 11.1% (n=10 cells across 8 animals) for α5+/+ and
149.8 ± 4% (n=8 cells across 6 animals) for α5-/- mice and, for
60mM ethanol application, was 131.8 ± 11.4% (n=7 cells
across 5 animals) for α5+/+ and 132.6 ± 12.3% (n=8 cells
across 5 animals) for α5-/- mice (Figure 5C).
Discussion
The α4β2* nAChR is widely expressed in the brain and
within the ventral tegmental area (VTA) the α5 is an accessory
subunit expressed predominantly in (α4β2) 2α5 nAChRs
[44,47,48]. There is considerable evidence in in vitro cell-based
systems that the inclusion of α5 subunit can regulate the
pharmacological properties, Ca2+ permeability and ACh
sensitivity of α4β2 nAChR cell lines [30,31,33,49]. Our study is
the first ex vivo evidence to show that the α5 nAChR subunit
controls α4*-containing nAChR expression in the ventral
tegmental area (VTA).
The first level of regulating nAChR expression is the
transcription of the subunits. The α5-/- mice were found to have
normal transcript levels for all nAChRs subunits, including α4
and β2 in all brain areas including the VTA [35,50]. Although in
midbrain dopamine neurons, there is no modulation of α4 and
β2 mRNA from birth through adulthood [51], there is a transient
increase in α5 mRNA shortly after birth (~p20) which declines
through adulthood. In studies involving cell-lines expressed in
oocytes, the subunit compositions of nAChRs expressed on the
cell surface are dependent on the relative proportions of
subunits (cDNAs) available for assembly [52,53]. The inclusion
of α5 subunit in the pool with α4 and β2 was shown to increase
the number of high binding affinity site measured by [3H]
epibatidine in HEK cells compared to the α4β2 parent line [31].
Hence it may be possible that the postnatal surge in α5 mRNA
could be facilitating the increase in α4*-containing nAChRs in
Figure 4.  The presence of α5α4* nAChR protects
receptors against desensitization to nicotine exposure.  (A)
The amplitude of a 300 ms ACh-induced sample current trace
elicited every 2 min during a 10 min exposure to nicotine (0.3
µM) is reduced from baseline in neurons from both α5+/+
(black) and α5-/- (gray) mice. (B) The time course of the
reduction of current from baseline for a 10 min exposure of 0.3
µM nicotine in α5+/+ and α5-/- mice. (C) The average percent
of baseline current after 10 min of 0.3 µM nicotine exposure. In
B&C, n=8-10 cells across 8-9 animals. The values in B&C are
reported as mean percent of baseline ± SEM (two-way ANOVA
followed by Neuman-Keuls post hoc test, *p<0.05). The
calibrations for the current trace are 25 pA, 0.5 sec.
doi: 10.1371/journal.pone.0068300.g004
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the VTA of α5+/+ mice. Because of the lack of α5 mRNA in the
knockout mice, the number of α4*-containing nAChRs is
reduced. This is how α5 may influence the assembly of α4*-
containing nAChRs in the VTA. The reduced α4 protein levels
measured here could be at the surface or intracellular or both.
Hence determining if this regulation of α4 nAChR subunit
expression has key implication for cholinergic function in the
ventral tegmental area becomes important.
We find that greater number of α4*-containing nAChRs in the
presence of α5 strengthens nicotinic receptor currents in VTA
dopaminergic neurons. Nicotinic currents in both α5 +/+ and α5
-/- mice were almost fully inhibited by the α4* nAChR
antagonist DHβE, suggesting that the ACh-induced nAChR
currents in VTA dopaminergic neurons were predominantly
mediated by α4*-containing nAChRs, and that the presence of
the α5 subunit in the α4* nAChR assembly boosted receptor
currents. A caveat in our study is that electrophysiological
recordings were done in animals between postnatal p21-p28
and the western blot analysis was done in animals between
p35-p70. However previous studies indicate it is unlikely that
there would be any difference in the expression or current
between these two age groups [51,54]. The stronger current in
the presence of α5 is consistent with studies involving non-
neuronal cell lines where the coexpression of α5 with α4β2
nAChRs produced larger currents than α4β2 alone [30].
Figure 5.  The presence of α5α4* nAChR does not affect
ethanol-mediated potentiation of ACh-induced nicotinic
current.  (A) The amplitude of a 300 ms ACh-induced sample
current trace elicited every 2 min during a 10 min exposure to
ethanol (80 mM) is increased from baseline in neurons from
α5+/+ (black) and α5-/- (gray) mice. (B) The time course of the
potentiation of current from baseline for a 10 min exposure of
80mM ethanol in α5+/+ and α5-/- mice. (C) The average
percent of baseline current after 10 min of 60 mM and 80 mM
ethanol exposure for α5+/+ and α5-/- mice. In B&C, n= 5-10
cells across 5-8 animals. The values in B&C are reported as
mean percent of baseline ± SEM (two-way ANOVA followed by
Neuman-Keuls post hoc test). The calibrations for the current
trace are 25 pA, 0.5 sec.
doi: 10.1371/journal.pone.0068300.g005
Additionally, one brain slice recording study in the prefrontal
cortex showed increases in the amplitude of nicotinic receptor
currents in cortical neurons of α5+/+ mice compared to α5-/-
mice [32]. Studies from heterologous cell line suggest that the
inclusion of α5 with α4β2 yield larger currents because of the
formation of higher conductance channel with greater Ca2+
permeability [30,49]. Our observation of a critical role for α5 in
maintaining expression of VTA α4* receptors suggests that the
reduced strength of the nicotinic current in the absence of α5 is
likely due to a reduced α4* nAChRs protein levels on the cell
surface. However further molecular studies would be required
to validate surface expression change. One of the functions of
increased Ca2+ permeability through nAChR is thought to
increase the excitability of the neuron and modulate
neurotransmitter release [55]. Hence, the reduced nicotinic
current in dopamine neurons is likely to affect excitability in the
α5-/- mice.
The α5 subunit is clearly an important accessory component
of the α4* nAChR assembly in the brain. Moreover, human
genetic association studies have indicated that the minor allele
of rs16969968 in CHRNA5, encoding a single nucleotide
polymorphism in the α5 subunit of the nAChR, to be associated
with increased risk of nicotine dependence [21,56] and
association with the level of alcohol response to an alcohol
challenge and dependence [20,23].
The human genetic studies have been complemented well
with behavioral animal studies to show that α5*-containing
nAChRs are important for nicotine [35,36,57]. Additionally,
previous studies have shown the α4*-containing nAChRs to be
important for the reinforcing properties of nicotine [24,58].
Nicotine can increase the release of dopamine
neurotransmitter in the striatum facilitating the reward-related
dopamine signal [59,60]. In vitro studies have shown nicotine at
high concentrations (or prolonged exposure at low
concentrations) can cause desensitization of nAChRs on
dopaminergic neurons [19,61] and thereby regulating striatal
dopamine release [62]. We found that prolonged exposure to
nicotine at concentrations achieved by smokers [19,63] induces
desensitization of nAChRs on VTA dopaminergic neurons,
which is significantly enhanced in the absence of the α5
subunit. This increased nAChR desensitization in the VTA
dopaminergic neurons likely reduces sensitivity to nicotine and
decreases striatal dopaminergic release, which could explain
the reduced sensitivity to high doses of nicotine [35] and
increased nicotine self-administration [36] in α5-/- mice. These
results about the α5-/- nicotinic receptors become particularly
relevant in understanding the role of CHRNA5 polymorphisms
for nicotine dependence in humans [64–66].
The behavioral role of α5 in ethanol’s effect has been shown
to modulate the sedative effects but not ethanol consumption in
mice [67]. Previous studies have shown ethanol-induced
activation of the VTA DA neurons in vivo and during in vitro
brain slice electrophysiology [6,68]. The interaction of ethanol
with the nAChR ion channel was first demonstrated in Torpedo
nAChRs, where ethanol enhances binding affinity of ACh to
this receptor [69]. Ethanol can potentiate the currents evoked
by ACh in cultured cortical neuronal cells [15,70] and Xenopus
oocytes expressing different subunit compositions nAChRs
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[16,71]. Here, we observed that ethanol potentiates ACh-
induced nicotinic currents in slice recording from the VTA, with
similar potentiation in neurons from both α5+/+ and α5-/- mice.
Hence, the α4*-containing nAChRs participated in ethanol’s
potentiation of ACh-evoked current irrespective of the α5
subunit. To the best of our knowledge, this is also the first
report of ethanol’s effect on ACh evoked currents in the
dopaminergic neurons of the VTA, consistent with oocyte
studies showing that α4β2 nAChRs were potentiated with
ethanol (75mM) [16,17]. Together, the α5* nAChRs appear to
play a key role in the pharmacology of nicotine but not ethanol
modulation of nicotinic currents in VTA dopaminergic neurons.
Our observation that α4α5* nAChR appear to not play a
regulatory role in ethanol’s effect is not completely surprising.
In behaving animals studies using null mutant mice of the β2
nAChR subunits [72], α4 nAChR subunits [73] and α5 nAChR
subunits [67] found no role in baseline ethanol consumption. In
addition, pharmacological manipulation using the α4* nAChR
antagonist DHβE showed no effect on ethanol intake [74].
Moreover, recent studies indicate the α3β4* rather than the
α4β2* nAChRs may play an important role in regulating ethanol
consumption [75]. Although most α5 is likely associated with
the α4 subunits, there is also some evidence that the α5
subunit may also be present in α3β4* nAChRs [76], which can
also modulate desensitization, pharmacology, Ca2+
permeability of human neuronal α3* nAChRs in recombinant
assays and non-neuronal expression systems [76,77].
Nonetheless, most studies indicate a prominent association of
α5 subunits with the α4β2* complex [31,44,47].
In conclusion, we have shown the α5 subunit is critical for
maintaining the expression of α4* nAChR protein levels of the
VTA neurons and strengthening nicotinic currents in
dopaminergic neurons. The presence of α5 causes resistance
to nicotine desensitization but does not regulate ethanol
enhancement of ACh currents in VTA dopaminergic neurons.
The α5 nAChR subunit is an important component of the α4*
containing nAChRs and plays a vital role for nicotine’s effect in
the brain. The α5α4* nAChR appears to be a promising target
for at least the treatment for nicotine dependence.
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